News in brief - August 2013

Other new launches, licence changes and updates relevant to general practice.

Nipatra is a mint-flavoured chewable tablet formulation of sildenafil for erectile dysfunction.
Nipatra is a mint-flavoured chewable tablet formulation of sildenafil for erectile dysfunction.
  • A chewable tablet formulation of sildenafil (Nipatra) is now available for the treatment of erectile dysfunction.
  • Ditropan Elixir (oxybutynin) has been relaunched by Sanofi for the treatment of urinary frequency, urgency and urge incontinence and neurogenic bladder disorders. and for the treatment of nocturnal enuresis in children when other treatment has failed.
  • The licence for Strattera (atomoxetine) has been extended to include initiation of treatment in adults with ADHD when the presence of symptoms in childhood can be confirmed.
  • RoActemra (tocilizumab) can now be used in the management of juvenile idiopathic polyarthritis in children who have responded inadequately to previous therapy with methotrexate.
  • Amdipharm Mercury has launched Ampres (chloroprocaine), a spinal anaesthetic for use where the planned procedure should not exceed 40 minutes.
  • Patients with transfusion-dependent anaemia due to myelodysplastic syndromes associated with an isolated 5q deletion can now benefit from treatment with Revlimid (lenalidomide) when other treatments are unsuitable.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...